Participating in the financing were a group of private investors and Viravaxx’s parent company Biomay AG.
The capital raised in this round will be employed for advancing Viravaxx’s lead product, the hepatitis B vaccine VVX001 into a clinical proof of concept study, as well as completing the design of innovative vaccines for human rhinovirus (HRV), human immunodeficiency virus (HIV) and respiratory syncytial virus (RSV). In addition, a diagnostic multiplexed peptide array designed for analysis of the IgG response to HRV infection will be prepared for marketing to the research market.
Rainer Henning, CEO of Viravaxx commented: “We are very grateful for the commitment of our new investors, who recognized the potential of our approach. We now have the resources available to demonstrate the clinical feasibility of our lead product VVX001. We have received already significant interest from prominent researchers in the respiratory field in our prospective HRV diagnostic tool. We look forward to make it available to them in the near future.”